Category: GlaxoSmithKline

Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis

Bart Scott, MD Professor, Transplantation Program Clinical Research Division Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair Fred Hutchinson Cancer Center Seattle, WA Targeted Oncology: Could you summarize the approved Janus kinase (JAK) inhibitors for patients with myelofibrosis? BART SCOTT, MD: Ruxolitinib (Jakafi) was approved in 2011, fedratinib (Inrebic) in…

Continue Reading Pacritinib Shows Transfusion Independence Benefits in Myelofibrosis

80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Job Category Any CategoryJobInternshipWork from Home Job Type Any Job TypesFull-timePart-timeContractVolunteer Location Any CountryUKCanadaAustraliaPakistanIrelandGermanyUSASwedenNew ZealandMalaysiaRussiaNetherlandDubaiSwitzerlandJapanVietnamItalyDenmarkOnlineGeorgiaLatviaSingaporeChinaNetherlandsIndiaFranceBelgiumBrazilColombiaEuropeEstoniaThailandNorwayNigeriaQatarCambodiaUAESouth KoreaAustriaTurkeyworldwideADB CountriesIndonesiaSaudi Arabia Industry Any Industry athletic apparel and footwear Refugee AgencyAccredited registrarAeronauticsAerospaceAirlineappliance manufacturerArtificial Intelligencearts, entertainment, and recreation sectorAstronomical ResearchAutomationAutomativeAviationBankingBioinformaticsBroadcastingBusiness Administrationcar manufacturingchemicalCivic and Social OrganizationsCivil EngineeringConsumer goodsCreativity and Innovation DevelopmentCyber SecurityDairyingData analyticsDevelopmentDigitale-commerceEducationEducationElectric Power GenerationEnergyEngineeringEngineering Professional…

Continue Reading 80 parttime, contract internship, remotely Banking, Bioinformatics, Digital, e-commerce, Finance, Information Technology, Investment, Research industry

Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

DelveInsight’s “Non-Hodgkin lymphoma Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the NHL, historical and forecasted epidemiology as well as the Non-Hodgkin lymphoma market trends in the United States EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. {Delhi, India} To…

Continue Reading Non-Hodgkin Lymphoma Market to Register Incremental Growth | AbbVie and Genmab, Roche, AstraZeneca, 4SC AG, Innate Pharma,Teva Pharma, Eli Lilly, and other companies are expected to change the Market scenario by 2032, forecasts DelveInsight.

Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Systemic therapy and surgery have become mainstays in the treatment of patients with endometrial cancer, although further research is necessary to delineate the optimal use of radiation and later-line immunotherapy in this patient population, according to Hope Cottrill, MD. The phase 3 NRG-GY018 trial (NCT03914612) evaluated the efficacy and safety…

Continue Reading Individual Disease Histology and Local Control Are Key Considerations in Endometrial Cancer Care

Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…

Continue Reading Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

Cholangiocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 11, 2023 DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type,…

Continue Reading Cholangiocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Cholangiocarcinoma Pipeline report embraces…

Continue Reading Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results

By Jonathan D. Grinstein, PhD What a difference a year makes. Almost 12 months ago, the hopes of Stanford University physician-scientist Matthew Porteus, MD, PhD, to implement a genome editing therapy for sickle cell disease (SCD) seemed all but lost. On January 5, 2023, the company he co-founded, Graphite Bio,…

Continue Reading Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results

Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

PRESS RELEASE Published December 7, 2023 DelveInsight’s, “Glioma Pipeline Insight 2023” report provides comprehensive insights about 190+ companies and 130+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product…

Continue Reading Glioma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

Continue Reading Neoadjuvant Pembrolizumab Plus Chemo Improves pCR Across Key ER+ Breast Cancer Subgroups

RNA- Based Therapeutic Market worth $29.41 Bn by 2031

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global RNA- Based Therapeutic Market– by Drug Class (RNA Aptamer, siRNA, Antisense RNA, mRNA), By Therapeutic Area (Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP)), Trends,…

Continue Reading RNA- Based Therapeutic Market worth $29.41 Bn by 2031

Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

PRESS RELEASE Published December 6, 2023 DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by…

Continue Reading Osteoarthritis Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023

PRESS RELEASE Published December 4, 2023 DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product…

Continue Reading Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023

Global Diffuse Large B-cell Lymphoma Therapeutics Market

Global Diffuse Large B-cell Lymphoma Therapeutics Market Forecast 2023-2032 The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies the increasing incidence…

Continue Reading Global Diffuse Large B-cell Lymphoma Therapeutics Market

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Continue Reading Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Continue Reading Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Who are the leading innovators in rDNA expression systems for the pharmaceutical industry?

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity. Identifying where a particular innovation is on this…

Continue Reading Who are the leading innovators in rDNA expression systems for the pharmaceutical industry?

[Latest] Global DNA Repair Drugs Market to be Worth USD 10.4 billion by 2031 | Transparency Market Research Inc.

DNA Repair Drugs Market Rise in incidence of cancer and advancements in DNA sequencing technologies WILMINGTON, DELAWARE, UNITED STATES, October 26, 2023 /EINPresswire.com/ — The global DNA repair drugs market offers a unique insight into key trends shaping the industry world-wide and in the largest markets. Written by some…

Continue Reading [Latest] Global DNA Repair Drugs Market to be Worth USD 10.4 billion by 2031 | Transparency Market Research Inc.

Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

Niraparib and abiraterone acetate plus prednisone combination therapy also showed clinically relevant improvement versus standard of care in time to symptomatic progression and time to cytotoxic chemotherapy MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis (FA) of…

Continue Reading Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in Overall Survival in Patients with mCRPC with BRCA Alterations Treated with Niraparib and Abiraterone Acetate Plus Prednisone

Final Multivariate Analysis from the Phase 3 MAGNITUDE

Niraparib and abiraterone acetate plus prednisone combination therapy also showed clinically relevant improvement versus standard of care in time to symptomatic progression and time to cytotoxic chemotherapy1 BEERSE, BELGIUM, Oct. 22, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis…

Continue Reading Final Multivariate Analysis from the Phase 3 MAGNITUDE

Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran (NASDAQ:ALNY)

Cardiac amyloidosis OGphoto Alnylam logo We rate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company’s next-generation inverse RNA or RNAi candidate, in treating cardiac amyloidosis in…

Continue Reading Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran (NASDAQ:ALNY)

ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

A 2020 Nature Cancer study found that patients with advanced non-small cell lung cancer (NSCLC) who had undetectable circulating tumor (ct)DNA after chemoradiotherapy “had excellent outcomes whether or not they received consolidation immune checkpoint inhibition (CICI) … the ctDNA response pattern early during CICI identified patients responding to consolidation therapy.”…

Continue Reading ASCO Reading Room | Circulating Tumor DNA: Up-and-Coming in Early-Stage NSCLC, On Deck in Advanced Disease

Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals and Emerging Drugs 2023 (Updated)

PRESS RELEASE Published September 30, 2023 DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis pipeline…

Continue Reading Eosinophilic Esophagitis Pipeline, Clinical Trials, FDA Approvals and Emerging Drugs 2023 (Updated)

Aquaculture Vaccine Market Poised to reach US$ 913.6 Million by 2033, Fuelled by Rising Global Aquaculture Production: FMI Study

The global Aquaculture Vaccines Market is worth US$ 406 Million as of now and is expected to reach US$ 913.6 Million by the year 2033 at a CAGR of 8.5% between 2023 and 2033. Surge in aquaculture is the factor majorly driving the aquaculture vaccines market. There is an ever-increasing…

Continue Reading Aquaculture Vaccine Market Poised to reach US$ 913.6 Million by 2033, Fuelled by Rising Global Aquaculture Production: FMI Study

Industry Growth, Revenue, and Demand Scope by Top Key Players and Future Prospects by 2030

PRESS RELEASE Published September 25, 2023 “Final Report will add the analysis of the impact of COVID-19 on this industry.”   The most recent global “Occupational Medicine Market” research report for 2023–2029 offers in-depth details on market demand, present trends, and most recent modifications that are anticipated to have an…

Continue Reading Industry Growth, Revenue, and Demand Scope by Top Key Players and Future Prospects by 2030

Respiratory Syncytial Virus Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

PRESS RELEASE Published September 21, 2023 DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the Respiratory Syncytial Virus pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Respiratory…

Continue Reading Respiratory Syncytial Virus Pipeline, Clinical Trials Assessment, FDA Approvals 2023 (Updated)

Gene Therapy Market to reach $17.2 billion by 2030, at CAGR

Gene Therapy Market The Gene Therapy Market has emerged as a groundbreaking frontier in modern medicine, offering hope and tangible solutions for a wide array of genetic and acquired disorders. One of the most notable trends in recent years has been the surge in FDA approvals for gene therapy products….

Continue Reading Gene Therapy Market to reach $17.2 billion by 2030, at CAGR

FDA Approves Momelotinib to Treat Myelofibrosis With Anemia

Momelotinib (Ojjaara) was granted FDA approval for the treatment of adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis- or secondary myelofibrosis-related anemia. 1 The regulatory decision is supported by findings from a subpopulation of adult patients with anemia from the phase 3 SIMPLIFY-1 trial (NCT01969838) and the phase 3…

Continue Reading FDA Approves Momelotinib to Treat Myelofibrosis With Anemia

Transforming Medicine and Patient Care

PRESS RELEASE Published September 15, 2023 The Gene Therapy Market is at the forefront of medical innovation, offering a promising avenue for treating a wide range of genetic and rare diseases. Gene therapy involves the introduction, modification, or replacement of genetic material within a patient’s cells to correct or alleviate…

Continue Reading Transforming Medicine and Patient Care

DelveInsight Highlights Major Advances, Transformative Therapies, and 7+ Leading Players Wheeling the Anaplastic Large Cell Lymphoma Clinical Trial Pipeline Landscape

PRESS RELEASE Published September 7, 2023 The Anaplastic Large Cell Lymphoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anaplastic Large Cell Lymphoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to…

Continue Reading DelveInsight Highlights Major Advances, Transformative Therapies, and 7+ Leading Players Wheeling the Anaplastic Large Cell Lymphoma Clinical Trial Pipeline Landscape

Efficient gene knockout and genetic interactions: the IN4MER CRISPR/Cas12a multiplex knockout platform

Abstract Genetic interactions mediate the emergence of phenotype from genotype, but initial technologies for combinatorial genetic perturbation in mammalian cells suffer from inefficiency and are challenging to scale. Recent focus on paralog synthetic lethality in cancer cells offers an opportunity to evaluate different approaches and improve on the state of…

Continue Reading Efficient gene knockout and genetic interactions: the IN4MER CRISPR/Cas12a multiplex knockout platform

Recombinant DNA Technology Market Size [2023-2030]

Fortune Business Insights Companies Profiled in the Recombinant DNA Technology Market Are Novartis AG, Thermo Fisher Scientific Inc., Sanofi Pasteur Limited, Merck KGaA, Genentech Inc., GlaxoSmithKline plc., Eli Lilly and Company, Pfizer Inc., Janssen Pharmaceuticals Inc., and others. Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The global recombinant DNA…

Continue Reading Recombinant DNA Technology Market Size [2023-2030]

Recombinant DNA Technology Market Size [2023-2030] |

Pune, India, Sept. 04, 2023 (GLOBE NEWSWIRE) — The global recombinant DNA technology market is expected to grow during 2023 to 2030. The growth of the market is driven by the increasing demand for recombinant DNA-based products and services in the healthcare, agricultural, and industrial sectors. The global recombinant DNA…

Continue Reading Recombinant DNA Technology Market Size [2023-2030] |

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the…

Continue Reading Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain

PRESS RELEASE Published September 1, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Acne Vulgaris Pipeline constitutes 22+ key companies continuously working towards developing 22+ Acne Vulgaris Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.   In the…

Continue Reading Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain

Cholangiocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

PRESS RELEASE Published August 31, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Cholangiocarcinoma Pipeline report embraces…

Continue Reading Cholangiocarcinoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

PRESS RELEASE Published August 25, 2023 List of reports available with us. Bone Cancer Treatment Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Vaccine Market Size / CAGR / Sales Revenue   (Request…

Continue Reading The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells

Cells and culture conditions NRC CHO2353™ cell lines have been described previously16,17. CHO2353 is a clone derived from CHO-DXB11 cells which were selected based on its high production yields of recombinant proteins. A complete description of the origin and selection of this clone can be consulted in ref. 15. Clone…

Continue Reading Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells

Diffuse Large B-cell Lymphoma Therapeutics Market 2023-2032:

Diffuse Large B-cell Lymphoma Therapeutics Market The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies increasing incidence of diffuse large B-cell…

Continue Reading Diffuse Large B-cell Lymphoma Therapeutics Market 2023-2032:

Bioinformatics Platforms Market 2023-2028 Global Key Manufacturers

PRESS RELEASE Published August 9, 2023 The Bioinformatics Platforms Market report outlines the evolution of Bioinformatics Platforms Market by type, applications and identifies and assesses the best performing vendors in the market till 2028. Bioinformatics Platforms Market reports present the revenue opportunities in the Bioinformatics Platforms Industry through 2023-2028, highlighting the market…

Continue Reading Bioinformatics Platforms Market 2023-2028 Global Key Manufacturers

What is Cancer immunotherapy targeting STING?

What is Cancer immunotherapy targeting STING?   What is Cancer immunotherapy targeting STING? Over the past decade, cancer immunotherapy using immune checkpoint inhibitors has achieved unprecedented success in cancer treatment; however, only a small fraction ( 10-35% ) of patients can derive clinical benefit from this treatment, Therefore, there is…

Continue Reading What is Cancer immunotherapy targeting STING?

Selinexor Maintenance Demonstrates Efficacy in TP53 Wild-Type Advanced Endometrial Cancer Following Frontline Chemotherapy

Compared with placebo, selinexor (Xpovio) maintenance therapy garnered superior progression-free survival (PFS) in patients with TP53 wild-type advanced or recurrent endometrial cancer who had received chemotherapy as frontline treatment, according to updated data from a prespecified subgroup analysis of the phase 3 SIENDO trial (NCT03555422).1 Long-term findings presented at the 2023 ASCO…

Continue Reading Selinexor Maintenance Demonstrates Efficacy in TP53 Wild-Type Advanced Endometrial Cancer Following Frontline Chemotherapy

Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer

Selinexor (Xpovio) maintenance generated an improvement in progression-free survival (PFS) compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy, according to updated data from a prespecified subgroup analysis of the phase 3 SIENDO trial (NCT03555422).1 Long-term findings presented at the 2023…

Continue Reading Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer

Bispecific Antibody Market revenue to cross USD 1 Billion

New York, July 24, 2023 (GLOBE NEWSWIRE) — The global bispecific antibody market size is slated to expand at ~7% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 1 billion by the end of 2035, up from a revenue of ~USD 500 million…

Continue Reading Bispecific Antibody Market revenue to cross USD 1 Billion

Rise in Consumption of Salmon and Tilapia to drive the Aquaculture Vaccines Market, reaching US$ 913.6 Million by the year 2033 a CAGR of 8.5%

The global Aquaculture Vaccines Market is worth US$ 406 Million as of now and is expected to reach US$ 913.6 Million by the year 2033 at a CAGR of 8.5% between 2023 and 2033. Surge in aquaculture is the factor majorly driving the aquaculture vaccines market. There is an ever-increasing…

Continue Reading Rise in Consumption of Salmon and Tilapia to drive the Aquaculture Vaccines Market, reaching US$ 913.6 Million by the year 2033 a CAGR of 8.5%

Oxford Nanopore Technologies plc Appoints Kate Priestman as Non-Executive Director

Oxford Nanopore Technologies plc announced that Kate Priestman will be joining the Group as Non-Executive Director with effect from 13 July 2023. Kate brings extensive experience as a biopharma executive for more than 25 years, serving in leadership roles across commercial, operations, corporate strategy, communications and government affairs. She was…

Continue Reading Oxford Nanopore Technologies plc Appoints Kate Priestman as Non-Executive Director

Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL | Ad-hoc

Genmab A/S / 09.11.2009 Dissemination of a Adhoc News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Summary: Genmab has initiated a Phase III study of Arzerra ofatumumab in diffuse large B-cell lymphoma. Copenhagen,…

Continue Reading Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL | Ad-hoc

TB Vaccine Candidate Receives $550M Boost For Phase 3 Trial

The third phase of the clinical trials is expected to have 26,000 participants, including those living with HIV and without TB infection, across more than 50 sites in Africa and SouthEast Asia. A tuberculosis (TB) vaccine candidate that has shown modest efficacy rates received a $550 million boost from the…

Continue Reading TB Vaccine Candidate Receives $550M Boost For Phase 3 Trial

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual data from 13 clinical studies of…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies

Chronic Obstructive Pulmonary Disease Pipeline Drugs 2023 (Updated): FDA Approvals, Clinical Trials, MOA, ROA

PRESS RELEASE Published June 23, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight….

Continue Reading Chronic Obstructive Pulmonary Disease Pipeline Drugs 2023 (Updated): FDA Approvals, Clinical Trials, MOA, ROA

Over the Counter (OTC) Analgesics Market to Reach US$ 39.74

Burlingame, June 23, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, global over the counter (OTC) analgesics market is estimated to be valued at US$ 28.55 billion in 2023 and is expected to exhibit a CAGR of 4.8% during the forecast period (2023-2030). Analysts’ Views on Global Over the Counter…

Continue Reading Over the Counter (OTC) Analgesics Market to Reach US$ 39.74

Biotechnology Market to Witness Enhanced Growth During 2023-2030 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline

The global biotechnology market was valued at US$ 518.3 Bn in 2022 and is forecast to reach a value of US$ 1,303.1 Bn by 2030 at a CAGR of 12.3% between 2023 and 2030. The most recent report published by Coherent Market Insights indicates that the Biotechnology Market is likely to accelerate…

Continue Reading Biotechnology Market to Witness Enhanced Growth During 2023-2030 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline

Gout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023

PRESS RELEASE Published June 17, 2023 “USD Analytics | Gout Therapeutics Market” The Asia Pacific region represents a significant market for gout therapeutics due to its large population. Countries like China, Japan, India, South Korea, and Australia contribute to the overall market size Gout Therapeutics Market Overview Analysis According to…

Continue Reading Gout Therapeutics Market Challenges, Drivers, Growth Opportunities, and Major Company Profiles 2023

A Comprehensive Study Exploring Plant-based Vaccines Market

PRESS RELEASE Published June 12, 2023 The latest study released on the Global Plant-based Vaccines Market by AMA Research evaluates market size, trend, and forecast to 2028. The Plant-based Vaccines market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and…

Continue Reading A Comprehensive Study Exploring Plant-based Vaccines Market

New Insight into Protein Interactome May Spur Drug Development and Novel Clinical Laboratory Tests

Study may lead to repurposing existing drugs that are proven to be safe for the treatment of related diseases as the interactome becomes the subject of more research efforts Researchers from multiple scientific institutions working together have begun using the protein interactome to understand what combination of unique biomarkers is…

Continue Reading New Insight into Protein Interactome May Spur Drug Development and Novel Clinical Laboratory Tests

Fanconi Anemia Market to see Huge Growth by 2031

PRESS RELEASE Published June 9, 2023 The Latest Research Report on Fanconi Anemia Market 2023 covering the micro level of analysis by competitors and key business segments. The Global Fanconi Anemia explores an inclusive study on various segments like growth drivers, opportunities, market size, shares, development, innovation, sales, and overall…

Continue Reading Fanconi Anemia Market to see Huge Growth by 2031

Large scale proteomic studies create novel privacy considerations

Funding Support and Acknowledgements: COPDGene: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung,…

Continue Reading Large scale proteomic studies create novel privacy considerations

Cancer Gene Therapy Market : Opportunity Analysis and Industry Forecast 2030 | CAGR 23.3%

Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. There are many techniques used for…

Continue Reading Cancer Gene Therapy Market : Opportunity Analysis and Industry Forecast 2030 | CAGR 23.3%

News at a glance: A respiratory disease vaccine, observing intensifying cyclones, and shaking a tall wooden building | Science

ENGINEERING Tall wood building is shaken, but not scathed A 10-story wooden building survived two severe, simulated earthquakes intact this week as scientists sought to show that wood can rival steel and concrete to safely support tall buildings. The structure is the tallest ever tested at the University of California,…

Continue Reading News at a glance: A respiratory disease vaccine, observing intensifying cyclones, and shaking a tall wooden building | Science

OTC Consumer Health Market Huge Growth in Future Scope 2023-2030

  Drugs that can be purchased over-the-counter do not require a prescription. Aches, pains, and itches can be treated with some OTC medications. Some treat or prevent conditions including athlete’s foot and tooth rot. Other over-the-counter medicines could assist in managing chronic conditions including allergies and migraines. When used as…

Continue Reading OTC Consumer Health Market Huge Growth in Future Scope 2023-2030

Why the human genome could be health care’s holy grail

Yahoo Finance published this video item, entitled “Why the human genome could be health care’s holy grail” – below is their description. #youtube #stockmarket #genetics 23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the…

Continue Reading Why the human genome could be health care’s holy grail

ImmunoGen Shares Takes Flight On Ovarian Cancer Survival Data

vadimrysev Investment Overview ImmunoGen (NASDAQ:IMGN) – an under the radar, Waltham, Massachusetts based biotech founded in 1981 sent its shareholders into raptures yesterday after publishing new data from its Phase 3 MIRASOL study of its drug ELAHERE, in patients with FRα-Positive, Platinum-Resistant Ovarian Cancer (“PROC”). Prior to yesterday’s news, ImmunoGen…

Continue Reading ImmunoGen Shares Takes Flight On Ovarian Cancer Survival Data

5 medical advances that will change patient care

Gene sequencing at record speeds to identify dangerous mutations. A treatment that delays Type 1 diabetes for years. A vaccine to prevent RSV infections, which kill thousands of Americans each year. Below we describe these and other recent developments in academic medicine that could help save the lives of millions…

Continue Reading 5 medical advances that will change patient care

Diffuse Large B-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight

PRESS RELEASE Published April 25, 2023 DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma. DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Diffuse Large B-cell Lymphoma,…

Continue Reading Diffuse Large B-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight

Welcome To IANS – India’s Largest Independent News Service

H2O World Comes to India For The First Time, Coinciding With The Rise of AI and Data Science Talent in the Country Business Wire India The AI cloud leader, H2O.ai, announced that H2O World India is set to take place on Wednesday, April 19th at the Leela Bhartiya…

Continue Reading Welcome To IANS – India’s Largest Independent News Service

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Competing interests A.R. is a founder, equity owner, and consultant at Halo Solutions and has served as a consultant at Tyra Biosciences. J.F.G. has served as a compensated consultant or received honoraria from Bristol Myers Squibb, Genentech/Roche, Ariad/Takeda, Loxo/Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, Mirati, AstraZeneca, Pfizer, Novartis, iTeos, Nuvalent,…

Continue Reading Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Phylogenomic analysis uncovers a 9-year variati…

Your new post is loading… Your new post is loading… Scooped by Ed Rybicki Scoop.it! Scooped by Ed Rybicki Scoop.it! This study has helped elucidate the responses underlying susceptibility to H5N1 influenza in avian species, which will be critical in developing sustainable strategies for future control of HPAI in domestic…

Continue Reading Phylogenomic analysis uncovers a 9-year variati…

Epithelial Ovarian Cancer Drugs Market Research Report Forecasted Data From 2023 To 2029

PRESS RELEASE Published April 5, 2023 Epithelial Ovarian Cancer Drugs market research is a report that is the result of careful investigation into relevant and useful data. The data that was examined took into account both existing top players and potential new competitors. Epithelial Ovarian Cancer Drugs the leading companies’…

Continue Reading Epithelial Ovarian Cancer Drugs Market Research Report Forecasted Data From 2023 To 2029

GSK Vaccine for Respiratory Syncytial Virus Shows High Efficacy in Older Adults

A single dose of the RSVPreF3 OA vaccine was effective against respiratory syncytial virus (RSV)-related acute respiratory infection (ARI) and lower respiratory tract (LRT) disease and severe RSV-related LRT disease among adults aged 60 years of age and older in 1 RSV season, according to study findings published in the…

Continue Reading GSK Vaccine for Respiratory Syncytial Virus Shows High Efficacy in Older Adults

SR One closes biotech fund at $600M

SR One, a transatlantic life sciences investment firm, has announced the close of its second fund at more than $600 million, exceeding its target of $500 million.  Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm….

Continue Reading SR One closes biotech fund at $600M

Which DNA test is best? We compare the major brands.

About 30 million people(Opens in a new tab) had a home DNA test done in early 2020. This number could be as high as 100 million(Opens in a new tab) in the next 24 months if MIT Technology Review’s predictions are correct. Success stories like finding a birth parent or…

Continue Reading Which DNA test is best? We compare the major brands.

The Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the forecast period

NEW YORK, March 15, 2023 /PRNewswire/ — Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027 Source: ReportLinker The analyst has been monitoring the diffuse large B-Cell Lymphoma (DLBCL) therapeutics market and is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the…

Continue Reading The Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market is forecast to grow by $ 2061.88 mn during 2022-2027, accelerating at a CAGR of 7.96% during the forecast period

ADC Therapeutics : Annual Report – Form 6-K

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

Continue Reading ADC Therapeutics : Annual Report – Form 6-K

Bridging the Gap to Reach Treatment Goals in DLBCL

CE Activity Release Date: March 15, 2023CE Activity Expiration Date: February 28, 2024 Time to Complete activity: 1 hour ACTIVITY DESCRIPTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been…

Continue Reading Bridging the Gap to Reach Treatment Goals in DLBCL

Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics – Technavio | PR Newswire

NEW YORK, March 10, 2023 /PRNewswire/ — The diffuse large B-cell lymphoma (DLBCL) therapeutics market size is forecast to grow by USD 2,061.88 million between 2022 and 2027, and the growth momentum will accelerate at a CAGR of 7.96% during the forecast period. The number of regulatory approvals for therapeutics…

Continue Reading Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics – Technavio | PR Newswire

Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics

NEW YORK, March 10, 2023 /PRNewswire/ — The diffuse large B-cell lymphoma (DLBCL) therapeutics market size is forecast to grow by USD 2,061.88 million between 2022 and 2027, and the growth momentum will accelerate at a CAGR of 7.96% during the forecast period. The number of regulatory approvals for therapeutics…

Continue Reading Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation | Journal of Hematology & Oncology

Jing Dong is supported by the Medical College of Wisconsin Cancer Center. N00014-17-1-2850 from the Office of Naval Research. The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and…

Continue Reading Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation | Journal of Hematology & Oncology

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Summary Background In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this…

Continue Reading Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

5 steps to strategic partnerships for healthtech startups

By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma…

Continue Reading 5 steps to strategic partnerships for healthtech startups

Protein Interactome Offers Key Resource for Drug Discovery and Repurposing

Proteins that physically bind each other are generally involved in the execution of similar biological functions and shape similar phenotypes at the organismal level in health and disease. A protein interactome—the network of all possible protein interactions—constitutes an important intermediary step that could bridge the often difficult to cross chasm…

Continue Reading Protein Interactome Offers Key Resource for Drug Discovery and Repurposing

RSV vaccine succeeds in phase 3 trial

Respiratory syncytial virus (RSV) is perhaps best known for causing severe illness in infants in children, but it leads up to 150,000 hospitalizations and 10,000 deaths in adults aged 65 and older each year, according to the Centers for Disease Control and Prevention (CDC). The ability of this virus to…

Continue Reading RSV vaccine succeeds in phase 3 trial

Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to reach US$ 28 billion by 2033, at a CAGR of 9.5%: Exclusive Report by Future Market Insights, Inc.

NEWARK, Del, Feb. 20, 2023 (GLOBE NEWSWIRE) — During the forecast period 2023 to 2033, the Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to grow at a value of 9.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Castration-Resistant Prostate Cancer (CRPC) Treatment…

Continue Reading Castration-Resistant Prostate Cancer (CRPC) Treatment Market is expected to reach US$ 28 billion by 2033, at a CAGR of 9.5%: Exclusive Report by Future Market Insights, Inc.

More than 100 years after the first TB vaccin

It has been more than 100 years since the first and only tuberculosis (TB) vaccine – the Bacillus Calmette–Guérin (BCG) vaccine – was used for the first time medically in 1921. With an estimated 1.6 million people dying from TB in 2021, there is an urgent need for new vaccines to help…

Continue Reading More than 100 years after the first TB vaccin

Systemic Sclerosis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook

PRESS RELEASE Published February 2, 2023 Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Systemic Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types….

Continue Reading Systemic Sclerosis Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook

Hepatitis C and HIV detection by blood RNA-sequencing in cohort of smokers

COPDGene Phase 3: Grant Support and Disclaimer: The project described was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National…

Continue Reading Hepatitis C and HIV detection by blood RNA-sequencing in cohort of smokers

AstraZeneca eagerness for CinCor revealed in larger first offer

AstraZeneca kicked off this year’s J.P.Morgan Healthcare Conference in style, announcing a $1.8 billion deal that gave it ownership of CinCor Pharma and its mid-phase hypertension drug baxdrostat. But while Fierce Biotech reported at the time that AstraZeneca was able to exploit CinCor’s deflated share price, that was only part…

Continue Reading AstraZeneca eagerness for CinCor revealed in larger first offer

Injectable Drugs Market Analysis of the Competitive Landscape, with a Forecast for 2027

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global injectable drugs market is relied upon to enlist a strong double-digit CAGR within the forecast period from 2019 to 2027. The market is majorly classified on the basis of drug-class, geography, molecule-type, and application. From the previous one entire…

Continue Reading Injectable Drugs Market Analysis of the Competitive Landscape, with a Forecast for 2027